Back to search
FDAFDA · Food and drugs·Recall number Z-1146-2019

Lactate Gen.2, Catalog Nos. 03183700190, 05171881190, 11822837190, ***added as of 5/10/19*** 03183700190 Product Usage: An In vitro diagnostic reagent system intended for use on cobas Integra for the quantitative determination of the lactate concentration in plasma and cerebrospinal fluid.

Published April 24, 2019 · Recall initiated: December 17, 2018

Summary

FDA records medical device Class II recall Z-1146-2019, published April 24, 2019 and initiated December 17, 2018. Recalling firm: Roche Diagnostics Corporation; Status: Terminated; Reported quantity: 5292 analytical units. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

New endogenous interference claims have been established for the following assays used on the cobas c 311 analyzer and the cobas c 501, 502, 701, 702, and Modular Analytics P/D modules which may have potential medical risk. ***Update: Cobas c111 and COBAS INTEGRA 400 plus analyzers are also impacted for BILT3 and LACT2 assays***

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Roche Diagnostics Corporation
Distributor
US Nationwide distribution.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Lactate Gen.2, Catalog Nos. 03183700190, 05171881190, 11822837190, ***added as of 5/10/19*** 03183700190 Product Usage: An In vitro diagnostic reagent system intended for use on cobas Integra for the quantitative determination of the lactate concentration in plasma and cerebrospinal fluid. recalled?

Yes. FDA published recall Z-1146-2019 on April 24, 2019. Reported hazard: New endogenous interference claims have been established for the following assays used on the cobas c 311 analyzer and the cobas c 501, 502, 701, 702, and Modular Analytics P/D modules which may have potential medical risk. ***Update: Cobas c111 and COBAS INTEGRA 400 plus analyzers are also impacted for BILT3 and LACT2 assays***

What should I do if I have this product?

Voluntary: Firm initiated · Letter